Tickers

1. Composite Trajectory Verdict

Given TMO's acquisitive business model and heavy capital deployment into M&A and share repurchases, all three statements carry weight, but the cash flow and balance sheet trajectories are most critical for assessing sustainability of the acquisition strategy.

Composite Trajectory: Mixed

The income statement shows consistent improvement across annual and quarterly periods: revenue, operating income, margins, and EPS all increased year-over-year. Cash generation presents a mixed picture: annual free cash flow declined from $7.3B (2024) to $6.3B (2025) despite higher net income, yet the first half of 2026 rebounded strongly to $2.5B versus $1.5B in H1 2025. The balance sheet is deteriorating: total debt rose 26% in 2025 to $39.4B and a further 8% in H1 2026 to $42.5B, while cash dropped from $9.9B to $4.1B in H1 2026 to fund the Clario acquisition and $4.0B of share repurchases.

2. Red Flags

• Annual operating cash flow declined for two consecutive years: $8.7B (2023) → $8.7B (2024) → $7.8B (2025) while net income rose each year (10-K 2025-12-31, Consolidated Statements of Cash Flows)
• Annual free cash flow fell 13% in 2025 to $6.3B from $7.3B in 2024 (10-K 2025-12-31, MD&A Liquidity and Capital Resources)
• Total debt increased $8.1B in 2025 (to $39.4B) and $3.2B in H1 2026 (to $42.5B) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-27, Liquidity and Capital Resources)
• Cash and equivalents fell 59% in H1 2026, from $9.9B to $4.1B, driven by $8.9B of acquisitions and $4.0B of buybacks (10-Q 2026-06-27, Consolidated Statements of Cash Flows)
• Valuation allowance on deferred tax assets jumped 3.4x to $3.6B at year-end 2025 from $1.0B at year-end 2024 (10-K 2025-12-31, Note 7)
• Restructuring charges recurred at $362M (2025), $379M (2024), $459M (2023) with additional $250M expected in 2026 (10-K 2025-12-31, Note 6)
• GAAP effective tax rate of 7.5% in 2025 and 6.5% in H1 2026 reflects large discrete benefits (domestication transactions, valuation allowance releases) that may not repeat (10-K 2025-12-31, Note 7; 10-Q 2026-06-27, Non-operating Items)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Revenue grew 4% in 2025 to $44.6B and 10% in Q2 2026 to $12.0B (10-K 2025-12-31, Consolidated Results; 10-Q 2026-06-27, Consolidated Results). GAAP operating income rose 6% in 2025 to $7.7B and 14% in Q2 2026 to $2.1B, with operating margin expanding 30bps annually (to 17.4%) and 50bps quarterly (to 17.4%) (same sources). GAAP diluted EPS increased 7% in 2025 to $17.74 and 9% in Q2 2026 to $4.68 (same sources). Organic revenue growth accelerated from 2% in 2025 to 5% in Q2 2026 (10-K 2025-12-31, Consolidated Results; 10-Q 2026-06-27, Consolidated Results). All four segments posted higher segment income in Q2 2026 versus Q2 2025 (10-Q 2026-06-27, Segment Results).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow declined to $7.8B in 2025 from $8.7B in 2024 and 2023, and annual free cash flow fell to $6.3B from $7.3B in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). The 2025 decline reflected $0.4B used for receivables, $0.4B for contract assets/liabilities, and $1.3B for other assets/liabilities tied to tax payment timing (10-K 2025-12-31, MD&A Operating Activities). In contrast, H1 2026 operating cash flow surged to $3.3B from $2.1B in H1 2025, and free cash flow rose to $2.5B from $1.5B, with the company noting "net income provided substantially all cash from operating activities" (10-Q 2026-06-27, Consolidated Statements of Cash Flows; MD&A Operating Activities). CapEx was $1.5B in 2025 and $0.8B in H1 2026, with full-year 2026 guided at $1.9–2.1B (10-K 2025-12-31, MD&A Investing Activities; 10-Q 2026-06-27, MD&A Investing Activities).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total debt rose from $31.3B at end-2024 to $39.4B at end-2025 (+26%) and to $42.5B at June 2026 (+8% in six months) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-27, Liquidity and Capital Resources). Cash and equivalents peaked at $9.9B at end-2025 but fell to $4.1B at June 2026 after $8.9B of acquisitions (primarily Clario) and $4.0B of share repurchases in H1 2026 (10-Q 2026-06-27, Consolidated Statements of Cash Flows). Goodwill increased to $49.4B at end-2025 from $45.9B at end-2024, with the new filtration and separation business reporting unit carrying $2.1B of goodwill at "not substantially in excess of its carrying value" (10-K 2025-12-31, Note 2; Critical Accounting Policies). Shareholders' equity grew to $53.4B from $49.6B, supported by retained earnings, but treasury stock expanded to $22.3B from $19.2B (10-K 2025-12-31, Balance Sheet). The revolving credit facility ($5.0B) remained undrawn at both dates (10-K 2025-12-31, Liquidity; 10-Q 2026-06-27, Liquidity).

6. Data Gaps

• Quarterly income statement and cash flow data for Q1 2026, Q3 2025, and Q2 2025 (only summarized in MD&A of subsequent filings)
• Full segment-level cash flow statements for any period
• Standalone Q3 2025 and Q4 2025 cash flow statements to bridge annual and H1 2026 figures
• Detailed debt maturity profile beyond the summary in Note 3 (only annual repayments shown)
• Organic revenue growth by segment for full-year 2024 and 2023 (only 2025 provided in 10-K)
• Free cash flow for 2023 (not explicitly stated in 10-K; can be derived as $8,406M operating cash flow less $1,479M CapEx = ~$6,927M)